Piramal Pharma Q2 Results Live : Piramal Pharma declared their Q2 results on 23 Oct, 2024, showcasing robust financial performance. The company’s topline saw a significant increase of 17.28% year-over-year, while profits skyrocketed by an impressive 350% during the same period.
In comparison to the previous quarter, Piramal Pharma’s revenue grew by 14.89%, and profit surged by 125.49%. This quarter’s results are a testament to the company’s effective operational strategies and market positioning.
Notably, the Selling, General & Administrative (SG&A) expenses saw a decline of 3.48% quarter-over-quarter, although they increased by 8.43% year-over-year, reflecting the company’s focus on cost management amidst growth.
Operating income also witnessed a commendable rise, up by 41.83% sequentially and 21.27% year-over-year, indicating a solid operational performance. The Earnings Per Share (EPS) for Q2 stood at ₹0.17, which marks a remarkable increase of 325% year-over-year.
Despite a slight dip of -6.19% in the last week, Piramal Pharma has delivered a staggering return of 57.11% over the last six months and 57% year-to-date. Currently, the company’s market cap stands at ₹28,770.91 Cr, with a 52-week high of ₹243.99 and a low of ₹87.5.
As of 24 Oct, 2024, the outlook for Piramal Pharma appears optimistic, with 3 out of 5 analysts giving a Buy rating and 2 analysts recommending a Strong Buy. The consensus recommendation remains a Strong Buy, reflecting confidence in the company’s future performance.
Piramal Pharma Financials
| Period | Q2 | Q1 | Q-o-Q Growth | Q2 | Y-o-Y Growth |
|---|---|---|---|---|---|
| Total Revenue | 2241.75 | 1951.14 | +14.89% | 1911.38 | +17.28% |
| Selling/ General/ Admin Expenses Total | 559.53 | 579.69 | -3.48% | 516.03 | +8.43% |
| Depreciation/ Amortization | 192.22 | 184.55 | +4.16% | 184.51 | +4.18% |
| Total Operating Expense | 1487.11 | 1419.07 | +4.79% | 1289.08 | +15.36% |
| Operating Income | 754.64 | 532.07 | +41.83% | 622.3 | +21.27% |
| Net Income Before Taxes | 120.12 | -45.08 | +366.46% | 39.56 | +203.64% |
| Net Income | 22.59 | -88.64 | +125.49% | 5.02 | +350% |
| Diluted Normalized EPS | 0.17 | -0.67 | +125.37% | 0.04 | +325% |
#Piramal #Pharma #Results #Live #Profit #Rises #YoY #Mint
Piramal Pharma Q2 result, Piramal Pharma, Piramal Pharma Q2, Piramal Pharma Quarterly Result, Q2 Result
latest news today, news today, breaking news, latest news today, english news, internet news, top news, oxbig, oxbig news, oxbig news network, oxbig news today, news by oxbig, oxbig media, oxbig network, oxbig news media
HINDI NEWS
